Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inotrem SA

www.inotrem.com

Latest From Inotrem SA

Venture Funding Deals: Late Summer Sees Slew Of Series B Mega-Rounds

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in August and September.

Deals Financing

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies

Appointments: Sanofi, MSD, Pandion, Orchard, Redx, Glythera, Inotrem

Companies filling positions include Sanofi, with a new head of business transformation, and MSD Research Laboratories, with a leader for its new London early discovery facility. There is new leadership for Pandion Therapeutics, and further C-suite appointments at Orchard Therapeutics, Redx Pharma, Glythera and Inotrem.

Appointments Leadership

The A-List: The Trend-Shaping Series A Financings Of 2014

In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Inotrem SA
  • Senior Management
  • Jean-Jaques Garaud, PhD, CEO
    Marc Derive, PhD, CSO
  • Contact Info
  • Inotrem SA
    Phone: 9 66 81 79 00
    114 rue la Boétie
    Paris, 75008
    France
UsernamePublicRestriction

Register